THE NEXT GENERATION OF VACCINES

Most infectious pathogens enter the body across mucosal surfaces. Yet few vaccines today provide mucosal immunity. NanoBio’s vaccines are different.

Our unique and patented adjuvant technology enables intranasal vaccines that elicit antibodies in the blood as well as across mucosal surfaces. These mucosal antibodies serve as “Bouncers at the Door” to keep infections out. Our studies point to increased protection against some of the world’s most severe respiratory and sexually transmitted diseases.

Vaccine Pipeline

NanoBio’s intranasal vaccine technology has demonstrated safety and immunogenicity in Phase 1 clinical studies for seasonal influenza. Several other programs have advanced through successful challenge studies in primary animal models. Choose a pathogen and click for details on our research results and partnering information.

Table showing NanoBio's research pipeline and vaccine statuses